Navigation Links
European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain
Date:3/28/2017

REDWOOD CITY, Calif., March 28, 2017 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, announced that the European Medicines Agency (EMA) has notified the company that the ARX-04 (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) has passed validation, and that the scientific review of the MAA is underway. The MAA for ARX-04 (known as DSUVIA™ in the U.S.) was filed in early March 2017 for the treatment of patients with moderate-to-severe acute pain in a medically supervised setting. AcelRx expects an opinion on the MAA from the Committee for Medicinal Products for Human Use (CHMP) in the first half of 2018.

"With regulatory filings for DSUVIA and ARX-04 now under review at the FDA and EMA, respectively, AcelRx has achieved an important milestone towards potentially having a commercial stage asset in multiple markets," stated Vincent Angotti, AcelRx's chief executive officer.  Mr. Angotti added, "We believe there is a significant opportunity in Europe for a product that allows healthcare professionals to efficiently deliver a 30 mcg dose of sublingual sufentanil through a pre-filled, single-dose applicator to patients suffering from moderate-to-severe acute pain."

The ARX-04 market in Europe is comprised of approximately 67 million adults who experience moderate-to-severe acute pain following short-stay surgery in hospitals and ambulatory surgery centers, or who receive care by ambulance services or in emergency departments for trauma or injuries.

About ARX-04 (known as DSUVIA™ in the US)
ARX-04 is a non-invasive investigational product candidate consisting of a 30 mcg sufentanil tablet delivered sublingually by a healthcare professional using a disposable, pre-filled, single-dose applicator (SDA). Dosing is as needed (prn) subject to a one hour minimum interval between dose administrations. Sufentanil is a synthetic opioid analgesic with a high therapeutic index and no known active metabolites.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, was accepted for filing by the FDA.

The Company's follow on product candidate, ZALVISO® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting, is currently enrolling patients in a Phase 3 clinical trial, IAP312. ZALVISO delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. ZALVISO is approved in the EU for the management of acute postoperative pain in a hospital setting and is investigational and in late-stage development in the U.S. Grunenthal Group holds the rights for ZALVISO in Europe, where a commercial launch has begun.

For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future development of AcelRx's product candidates, DSUVIATM (sufentanil sublingual tablet, 30 mcg), known as ARX-04 outside the United States, and ZALVISO® (sufentanil sublingual tablet system), including U.S. Food and Drug Administration, or FDA, review of the New Drug Application, or NDA, for DSUVIA; the potential approval of the DSUVIA NDA by the FDA; the DSUVIA and ARX-04 clinical trial results; AcelRx's pathway forward towards gaining approval of ZALVISO in the U.S., including successful completion of the IAP312 clinical study for ZALVISO; and the therapeutic and commercial potential of AcelRx's product candidates, including potential market opportunities for DSUVIA, ARX-04 and ZALVISO. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and timing of events could differ materially from those anticipated in such forward-looking statements, and as a result of these risks and uncertainties, which include, without limitation, risks related to AcelRx Pharmaceuticals' DSUVIA and ARX-04 development programs, including the FDA review of the DSUVIA NDA and the possibility that the FDA may dispute or interpret differently clinical results obtained from the DSUVIA Phase 3 studies; the ZALVISO development program, including successful completion of IAP312 and the resubmission of the ZALVISO NDA to the FDA; any delays or inability to obtain and maintain regulatory approval of its product candidates, including DSUVIA in the United States, ARX-04 in Europe and ZALVISO in the United States; the uncertain clinical development process; the success, cost and timing of all development activities and clinical trials; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K filed with the SEC on March 3, 2017. AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/european-medicines-agency-begins-evaluation-of-marketing-application-for-sublingual-sufentanil-30-mcg-tablet-arx-04-for-moderate-to-severe-acute-pain-300429856.html


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Surgery Without the Knife: Mirabilis Medical Announces European Approval for Non-Invasive Uterine Fibroid Treatment
2. Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress
3. La Roche-Posays My UV Patch Wins the European "Nudging for Good" Diamond Award
4. Omnicells Newest Automated Dispensing Solutions to Be Showcased at the European Association of Hospital Pharmacists Congress
5. Innovative Cardiovascular Solutions Announces Successful First Cases in European Clinical Study of EMBLOK Embolic Protection System
6. Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes
7. Frost & Sullivan Lauds SnooZeals Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market
8. Bioness Announces First European Implants for StimRouter Neuromodulation System
9. Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis
10. Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohns and Colitis Organization
11. Armetheon Announces European Medicines Agencys Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial Services, ... preparation services, is providing an update on a charitable event that began earlier ... is a locally recognized nonprofit that provides shelter and care for animals seeking ...
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
Breaking Medicine News(10 mins):